Nose Cancer, also known as Nasopharyngeal Cancer (NPC), occurs as a mass in the nasopharynx, which is behind the nose and above the back of the throat.
Individuals above 40 years old and Asian, as documented in a study of >20,000 Asian individuals. A virus called Epstein Barr Virus (EBV) is closely associated with the occurrence of nose cancer. Known risk factors include exposure to air pollution and family history of nose cancer
NPC GOLD is a cancer screening test with a focus on nose cancer by analysing the blood samples. This non-invasive test examines the presence of the DNA from EBV.
Improved detection of nose cancer at stages 1 and 2 with NPC GOLD™ allows early treatment to be implemented and it can lead to increased survival rates.
- If the patient is in the risk group.
- If the patient has a family member who has been diagnosed with nose cancer or you believe you are at risk.
- If the patient is experiencing nose bleeds, painless neck lumps, hearing loss, facial pain/numbness, and blurred/ double vision.
The patient should be recommended to repeat the NPC GOLD™ test 4 weeks later. If the result is again positive, the patient should be referred to an ENT specialist.
The patient should be recommended to do annual screening with NPC GOLD™ for early detection.